Clinical Trials Browser

Phase 1/2 × Burkitt Lymphoma × ibritumomab tiuxetan × Clear all

NCT00064246 2013-01-25

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Phase 1/2 Completed

Burkitt Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse